<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00331097</url>
  </required_header>
  <id_info>
    <org_study_id>ELDA</org_study_id>
    <nct_id>NCT00331097</nct_id>
  </id_info>
  <brief_title>ELDA: Elderly Breast Cancer - Docetaxel in Adjuvant Treatment</brief_title>
  <official_title>Adjuvant Chemotherapy in Elderly Patients With Breast Cancer: Weekly Docetaxel vs. CMF</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute, Naples</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute, Naples</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare disease free survival of elderly breast cancer
      patients treated with standard adjuvant chemotherapy (CMF) versus experimental adjuvant
      chemotherapy (weekly docetaxel).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Adjuvant combination chemotherapy, given after breast cancer surgery, has been established as
      the standard approach to reduce the risk of breast cancer recurrence in those patients at
      intermediate or high risk for recurrence. However, since elderly patients have been
      underrepresented in past clinical trials, the optimal adjuvant therapy for elderly patients
      at risk for recurrence has not yet been defined.

      Docetaxel is one of the most active drugs for patients with metastatic breast cancer and
      several trials are evaluating its efficacy in the adjuvant setting. Administration of
      docetaxel on a weekly schedule is effective and well tolerated in women with metastatic
      breast cancer.

      In this study, patients from ages 65 to 80 will be randomized to one of two treatment
      strategies:

        -  standard adjuvant chemotherapy with CMF (cyclophosphamide, methotrexate, and
           5-fluorouracil given intravenously on days 1 and 8 of each cycle)

        -  experimental adjuvant chemotherapy with weekly docetaxel (given intravenously on days
           1,8, and 15 of each cycle)

      In both treatment strategies:

        -  4 cycles of chemotherapy will administered for patients at least 10% positive for ER or
           PgR, and 6 cycles will administered for patients expressing &lt; 10% ER or PgR

        -  patients with any positive expression of ER or PgR will receive adjuvant hormonal
           therapy with tamoxifen (20mg/day for 5 years) after concluding chemotherapy

        -  adjuvant radiation therapy will be given to patients who are candidates at the
           conclusion of chemotherapy and within 6 months of surgery.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2003</start_date>
  <completion_date type="Actual">November 2014</completion_date>
  <primary_completion_date type="Actual">May 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>disease free survival</measure>
    <time_frame>at 5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>toxicity</measure>
    <time_frame>weekly</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>compliance</measure>
    <time_frame>every 3 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>quality of life</measure>
    <time_frame>baseline and every 3 weeks during therapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>at 5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">300</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard chemotherapy with CMF</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Weekly docetaxel</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>docetaxel</intervention_name>
    <description>35 mg/m2 intravenously on days 1, 8, and 15 every 28 days</description>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
    <description>600 mg/m2 intravenously days 1, 8 every 28 days</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>methotrexate</intervention_name>
    <description>40 mg/m2 intravenously days 1 and 8 every 28 days</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5-fluorouracil</intervention_name>
    <description>600 mg/m2 intravenously days 1 and 8 every 28 days</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed invasive unilateral breast cancer

          -  Age &gt; 65 and &lt; 80 years

          -  Intermediate-high risk of recurrence according to St. Gallen criteria: ER negative and
             PgR negative, or axillary lymph node metastasis, or tumor size &gt; 2 cm, or tumor grade
             2 or 3 (intermediate or high)

        Exclusion Criteria:

          -  Performance status &gt;1

          -  Distant metastasis

          -  Concomitant malignancy or malignancy within previous 5 years (except basal cell or
             spinocellular skin cancer and in situ cervical cancer if they have been adequately
             treated

          -  Previous breast cancer treatment

          -  Neutrophils &lt; 2000/mm3 or platelets &lt; 100000/mm3 or haemoglobin &lt; 10 g/dl

          -  Creatinine &gt; 1.25 the upper normal limit

          -  GOT and-or GPT and/or bilirubin &gt; 1.25 the upper normal limit

          -  Concomitant conditions that contraindicate the use of the drugs in the protocol

          -  Incapacity or refusal to provide informed consent
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrea De Matteis, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>NCI Naples, Division of Medical Oncology C</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Giuseppe D'Aiuto, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>NCI Naples, Division of Surgical Oncology A</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Francesco Perrone, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>NCI Naples, Clinical Trials Unit</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Azienda Sanitaria S. Giuseppe Moscati</name>
      <address>
        <city>Monteforte Irpino</city>
        <state>AV</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera G. Rummo</name>
      <address>
        <city>Benevento</city>
        <state>BN</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico Monteluce</name>
      <address>
        <city>Sant'Andrea delle Frate</city>
        <state>PG</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Cardarelli</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Nazionale dei Tumori, Divisione di Oncologia Medica C</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universit√† Federico II, Cattedra di Oncologia Medica</name>
      <address>
        <city>Napoli</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Az. Osp. Treviglio - Caravaggio</name>
      <address>
        <city>Treviglio</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale S. Luca ASL SA 3</name>
      <address>
        <city>Vallo della Lucania</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Nuzzo F, Morabito A, De Maio E, Di Rella F, Gravina A, Labonia V, Landi G, Pacilio C, Piccirillo MC, Rossi E, D'Aiuto G, Thomas R, Gori S, Colozza M, De Placido S, Lauria R, Signoriello G, Gallo C, Perrone F, de Matteis A. Weekly docetaxel versus CMF as adjuvant chemotherapy for elderly breast cancer patients: safety data from the multicentre phase 3 randomised ELDA trial. Crit Rev Oncol Hematol. 2008 May;66(2):171-80. Epub 2007 Dec 21.</citation>
    <PMID>18160303</PMID>
  </reference>
  <results_reference>
    <citation>Perrone F, Nuzzo F, Di Rella F, Gravina A, Iodice G, Labonia V, Landi G, Pacilio C, Rossi E, De Laurentiis M, D'Aiuto M, Botti G, Forestieri V, Lauria R, De Placido S, Tinessa V, Daniele B, Gori S, Colantuoni G, Barni S, Riccardi F, De Maio E, Montanino A, Morabito A, Daniele G, Di Maio M, Piccirillo MC, Signoriello S, Gallo C, de Matteis A. Weekly docetaxel versus CMF as adjuvant chemotherapy for older women with early breast cancer: final results of the randomized phase III ELDA trial. Ann Oncol. 2015 Apr;26(4):675-82. doi: 10.1093/annonc/mdu564. Epub 2014 Dec 8.</citation>
    <PMID>25488686</PMID>
  </results_reference>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 26, 2006</study_first_submitted>
  <study_first_submitted_qc>May 26, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 29, 2006</study_first_posted>
  <last_update_submitted>March 27, 2017</last_update_submitted>
  <last_update_submitted_qc>March 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>elderly</keyword>
  <keyword>adjuvant therapy</keyword>
  <keyword>intermediate risk</keyword>
  <keyword>high risk</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

